Log in
Enquire now
Verve Therapeutics

Verve Therapeutics

Verve Therapeutics is a company in Cambridge, Massachusetts.

OverviewStructured DataIssuesContributors

Contents

vervetx.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Internal medicine
Internal medicine
Therapeutics
Therapeutics
Biomedical engineering
Biomedical engineering
Technology
Technology
Cardiovascular disease
Cardiovascular disease
...
Location
United States
United States
Cambridge, Massachusetts
Cambridge, Massachusetts
0
B2X
B2B
B2B
CEO
Sekar Kathiresan
Sekar Kathiresan
Founder
Sekar Kathiresan
Sekar Kathiresan
0
‌
Kiran Musunuru
0
‌
Burt Adelman
0
J. Keith Joung
J. Keith Joung
0
Anthony Philippakis
Anthony Philippakis
0
Issi Rozen
Issi Rozen
‌
Barry Ticho
0
Pitchbook URL
pitchbook.com/profiles...267274-54
Legal Name
Verve Therapeutics, Inc
Number of Employees (Ranges)
51 – 200
Email Address
gina@tenbridgecommunication.com0
chelcie@thrustsc.com0
Phone Number
+161760300700
Full Address
500 Technology Square, Suite 901, Cambridge, Massachusetts 02139, US0
CIK Number
1,840,5740
Place of Incorporation
Delaware
Delaware
0
Investors
Biomatics Capital Partners
Biomatics Capital Partners
F-Prime Capital Partners
F-Prime Capital Partners
Casdin Capital
Casdin Capital
Redmile Group
Redmile Group
Surveyor Capital
Surveyor Capital
Cormorant Asset Management
Cormorant Asset Management
Janus Henderson Investors
Janus Henderson Investors
Logos Capital
Logos Capital
...
IRS Number
824,800,1320
Founded Date
2018
Total Funding Amount (USD)
309,499,993
Latest Funding Round Date
January 2021
Stock Symbol
VERV
Exchange
Nasdaq
Nasdaq
0
Board of Directors
Sheila Mikhail
Sheila Mikhail
0
‌
Burt Adelman
0
‌
Bo Cumbo
0
‌
Michael MacLean
0
‌
Lonnel Coats
0
Sekar Kathiresan
Sekar Kathiresan
0
Krishna Yeshwant
Krishna Yeshwant
0
CFO
‌
Allison Dorval
0
Key People
Sekar Kathiresan
Sekar Kathiresan
Latest Funding Type
Series B
Series B
Patents Assigned (Count)
1
Motto/Tagline
Verve Therapeutics was created with a singular focus: to protect the world from cardiovascular disease
Technologies Used
CRISPR
CRISPR
Country
United States
United States
Headquarters
Cambridge, Massachusetts
Cambridge, Massachusetts

Other attributes

Company Operating Status
Active
Contact Page URL
vervetx.com/contact-us/
SIC Code
2,8340
Ticker Symbol
VERV0

Verve Therapeutics is a biotechnology company. The company's gene editing medicines are designed to safely edit the genome of adults and mimic naturally occurring gene variants to permanently lower LDL cholesterol and triglyceride levels.

Verve Therapeutics is focused on using CRISPR and gene editing techniques to treat coronary artery and cardiovascular disease.

Verve Therapeutics was founded in 2018 by Sekar Kathiresan, and other researchers in the area of cardiovascular genetics including Kiran Musunuru and J. Keith Joung. Verve's initial two programs target PCSK9 and ANGPTL3, two genes which have been validated by human genetics and pharmacology to be targets for lowering blood lipids. The company completed its initial public offering on the Nasdaq in June 2021, raising gross proceeds of $266.7 million.

Official website

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Verve Therapeutics

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.